Post-Infusion Immunophenotypic and Functional Characteristics of Arlocabtagene Autoleucel (Arlo-Cel) in a First-In-Human (FiH), Phase 1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM) (IMS 2026) - Sep 11, 2026 - Abstract #PA-358; Pres time: Sep 25, 2026; P1 | "Arlo-cel phenotypic and functional characteristics suggest early anti-tumor activity, memory formation within the CD4+ CAR T cells, and resolution of the inflammatory state after tumor clearance. Early arlo-cel activation, proliferation, and supportive cytokine production mediate tumor eradication. After tumor clearance, memory evolution in the CD4+ CAR T compartment may support arlo-cel anti-MM surveillance, while resolution of inflammation may indicate target specific arlo-cel activity."
First-in-human • IO biomarker • P1 data • Hematological Malignancies • Multiple Myeloma • CD27 • CD4 • CD8 • CSF2 • IFNG • IL12A • IL15 • IL2 • IL6
|
|
Sifiyya Ziyad1; Kristina Jordahl1; Hongxiang Hu1; WeiMing Kao1; Ethan Thompson1; Shari Kaiser1; Susan Bal2
|